Patents by Inventor Aaron Almeida

Aaron Almeida has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibiting gene expression of Hif2alpha
    Patent number: 11840688
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: December 12, 2023
    Assignee: Arrowhead Pharmaceuticals, inc.
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF
    Publication number: 20220024975
    Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.
    Type: Application
    Filed: October 14, 2021
    Publication date: January 27, 2022
    Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
  • Alpha-v beta-6 integrin ligands and uses thereof
    Patent number: 11180529
    Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 23, 2021
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
  • Compositions and Methods for Inhibiting Gene Expression of Hif2alpha
    Publication number: 20210180066
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 17, 2021
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Compositions and methods for inhibiting gene expression of Hif2alpha
    Patent number: 10927373
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: February 23, 2021
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA
    Publication number: 20200263179
    Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
    Type: Application
    Filed: May 6, 2020
    Publication date: August 20, 2020
    Inventors: Stacey MELQUIST, Steven KANNER, David B. ROZEMA, David L. LEWIS, Lauren J. ALMEIDA, Darren H. WAKEFIELD, Vladimir S. TRUBETSKOY, Tao PEI, Zhen LI, Aaron ALMEIDA
  • Compositions and methods for inhibiting gene expression of LPA
    Patent number: 10662427
    Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: May 26, 2020
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Stacey Melquist, Steven Kanner, David B. Rozema, David L. Lewis, Lauren J. Almeida, Darren H. Wakefield, Vladimir S. Trubetskoy, Tao Pei, Zhen Li, Aaron Almeida
  • ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF
    Publication number: 20190248832
    Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 15, 2019
    Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
  • Compositions and Methods for Inhibiting Gene Expression of Hif2alpha
    Publication number: 20180230470
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Application
    Filed: April 16, 2018
    Publication date: August 16, 2018
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Disulfide-containing alkyne linking agents
    Patent number: 10047361
    Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: August 14, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Aaron Almeida, Andrei V. Blokhin, Darren H. Wakefield, Jonathan D. Benson, David B. Rozema
  • Compositions and Methods for Inhibiting Gene Expression of LPA
    Publication number: 20180195070
    Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
    Type: Application
    Filed: February 21, 2018
    Publication date: July 12, 2018
    Inventors: Stacey MELQUIST, Steven KANNER, David B. ROZEMA, David L. LEWIS, Lauren J. ALMEIDA, Darren H. WAKEFIELD, Vladimir S. TRUBETSKOY, Tao PEI, Zhen LI, Aaron ALMEIDA
  • Compositions and methods for inhibiting gene expression of Hif2alpha
    Patent number: 9976141
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: May 22, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Compositions and methods for inhibiting gene expression of LPA
    Patent number: 9932586
    Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 3, 2018
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Stacey Melquist, Steven Kanner, David B. Rozema, David L. Lewis, Lauren J. Almeida, Darren H. Wakefield, Vladimir S. Trubetskoy, Tao Pei, Zhen Li, Aaron Almeida
  • Disulfide-Containing Alkyne Linking Agents
    Publication number: 20180023084
    Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.
    Type: Application
    Filed: September 27, 2017
    Publication date: January 25, 2018
    Inventors: Aaron Almeida, Andrei V. Blokhin, Darren H. Wakefield, Jonathan D. Benson, David B. Rozema
  • Disulfide-containing alkyne linking agents
    Patent number: 9803201
    Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: October 31, 2017
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Aaron Almeida, Andrei V. Blokhin, Darren H. Wakefield, Jonathan D. Benson, David B. Rozema
  • Compositions and Methods for Inhibiting Gene Expression of LPA
    Publication number: 20170096665
    Abstract: RNA interference (RNAi) agents and RNAi agent conjugates for inhibiting the expression of the LPA (apo(a)) gene are described. Pharmaceutical compositions comprising one or more LPA RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described LPA RNAi agents to liver cells in vivo provides for inhibition of LPA gene expression and treatment of cardiovascular and cardiovascular-related diseases.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 6, 2017
    Inventors: Stacey Melquist, Steven Kanner, David B. Rozema, David L. Lewis, Lauren J. Almeida, Darren H. Wakefield, Vladimir S. Trubetskoy, Tao Pei, Zhen Li, Aaron Almeida
  • Compositions and Methods for Inhibiting Gene Expression of Hif2alpha
    Publication number: 20160348107
    Abstract: RNA interference (RNAi) triggers and RNAi trigger conjugates for inhibiting the expression of Hif2? (EPAS1) gene are described. Pharmaceutical compositions comprising one or more Hif2? RNAi triggers optionally with one or more additional therapeutics are also described. Delivery of the described Hif2? RNAi triggers to tumor cells in vivo provides for inhibition of Hif2? gene expression and treatment of cancer.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Inventors: So Wong, David L. Lewis, David B. Rozema, Darren H. Wakefield, Steven B. Kanner, Weijun Cheng, Lauren J. Almeida, Andrei V. Blokhin, Jeffrey C. Carlson, Anthony L. Nicholas, Aaron Almeida, Jonathan D. Benson, Justin Woods
  • Disulfide-Containing Alkyne Linking Agents
    Publication number: 20160272971
    Abstract: Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. The linking agents are useful for attachment of oligonucleotides to targeting groups or delivery agents.
    Type: Application
    Filed: March 16, 2016
    Publication date: September 22, 2016
    Inventors: Aaron Almeida, Andrei V. Blokhin, Darren H. Wakefield, Jonathan D. Benson, David B. Rozema